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Abstract A series of chimeras between the transmembrane
domains of phospholamban (PLN) and cytochrome b5 were
coexpressed with the Ca2+-ATPase of cardiac sarcoplasmic
reticulum (SERCA2a). The chimeric molecules were not
inhibitory, in line with our view that inhibitory PLN/SERCA2a
interactions occur in transmembrane sequences, while cytoplas-
mic interactions regulate the inhibitory interactions in a four-
base circuit.
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1. Introduction
Phospholamban (PLN) is a 52 amino acid, integral mem-
brane protein [1] that interacts with and reversibly inhibits the
activity of the cardiac sarcoplasmic reticulum Ca2-ATPase
(SERCA2a). In this role, it is a major regulator of the kinetics
of cardiac contractility [2]. The protein can be divided into
three domains: domain Ia, residues 1^20, is a charged, largely
helical, cytoplasmic domain; domain Ib, residues 21^30, is a
relatively unstructured sequence, rich in amidated residues;
and domain II, residues 31^52, is a transmembrane helix com-
posed of uncharged and hydrophobic amino acids.
Domain Ia contains a site for protein kinase A phospho-
rylation at Ser16 and a site for calmodulin kinase II phospho-
rylation at Thr17 [3]. Phosphorylation of domain Ia disrupts
both the inhibitory e¡ect of PLN on SERCA2a function [4]
and the physical interaction between the two molecules [5].
We have used coexpression and site-directed mutagenesis to
identify charged and hydrophobic amino acids in PLN do-
main Ia [6] and charged and hydrophobic amino acids, lying
between Lys397 and Val402 in the cytoplasmic domain of
SERCA2a [7], as the amino acids involved in PLN/SERCA2a
cytoplasmic interactions.
An increase in Ca2 concentration also disrupts PLN/
SERCA2a interactions [5]. Since the only sites of high a⁄nity
Ca2 binding in the PLN/SERCA2a complex lie in SERCA2a
transmembrane helices 4, 5 and 6 [8], it is probable that Ca2
binding to M4, M5 and M6 disrupts their inhibitory interac-
tions with PLN domain II. Studies by Sasaki et al. [9] showed
that the reconstitution of very high concentrations of soluble
PLN1ÿ28 with uninhibited SERCA2a resulted in a decrease in
Vmax, while reconstitution of very high concentrations of in-
soluble PLN28ÿ48 with uninhibited SERCA2a led to a de-
crease in KCa. On this basis, Sasaki et al. [9] proposed two
sites of inhibitory interaction between PLN and SERCA2a.
Further studies in other laboratories have either con¢rmed
[10,11] or failed to con¢rm [12] the inhibitory role of PLN
domain I. Another study [13] disputed the inhibitory role of
PLN domain II on the basis that it uncoupled ATP hydrolysis
from Ca2 transport.
We coexpressed PLN transmembrane domains with
SERCA2a and obtained clear evidence that the transmem-
brane interaction sites are the inhibitory sites [14]. These ob-
servations were strengthened by the use of alanine-scanning
mutagenesis to localize the site of transmembrane inhibitory
interactions to one face of the PLN transmembrane helix [15].
On this basis, we proposed a model in which the inhibitory
interaction sites are located in transmembrane helices and
non-inhibitory interactions occur in the cytoplasm. These
sites, however, form a four-base circuit, involving both cyto-
plasmic and transmembrane interaction sites in both PLN and
SERCA2a, which are coregulated by either phosphorylation
or elevated Ca2 or both [14].
In the continued evaluation of this model, we have created
a chimera between PLN cytoplasmic domain I and the trans-
membrane sequence of cytochrome b5 [16]. Coexpression
of this chimera with SERCA2a does not inhibit SERCA2a
function, in line with our proposal that cytoplasmic PLN/
SERCa2a interaction sites are not inhibitory.
2. Materials and methods
2.1. Synthesis of chimeric constructs, expression, assay and detection
of protein synthesis and phosphorylation
PLN and SERCA2a constructs, their coexpression, assay of their
synthesis by immunoblotting, assay of Ca2 transport function by
SERCA2a and assay of phosphorylation of PLN have been described
previously [14]. The rabbit cytochrome b5 (cytb5) construct was a kind
gift from Dr. David Andrews, McMaster University. PLN1ÿ21-
cytb5101ÿ134, PLN1ÿ29-cytb5109ÿ134, and PLN1ÿ44-cytb5124ÿ134 were
synthesized using a recombinant polymerase chain reaction [17].
Wild type and mutant cDNAs were ligated into the XbaI and SalI
sites of the pMT2 expression vector [18] prior to expression.
2.2. Immunostaining of transfected cells
Colocalization of SERCA2a and chimeric PLN was evaluated by
immunostaining of cells harvested at 48 h after transfection and ¢xed
and permeabilized in 5% acetic acid in ethanol for 5 min on ice. Cells
were incubated with rabbit polyclonal antibody C4 against SERCA2a
[19] and mouse monoclonal antibody 1D11 against PLN [20] (a kind
gift from Dr. Robert Johnson, Merck Research Laboratories), fol-
lowed by incubation with FITC-labelled anti-rabbit IgG and
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TRITC-labelled anti-mouse IgG and examination by confocal micros-
copy. Excitation wavelengths were 488 nm (FITC) and 568 nm
(TRITC) and emission wavelengths were 515^540 nm (FITC) and
590 nm (TRITC).
3. Results
Chimeric mutants PLN1ÿ21-cytb5101ÿ134, PLN1ÿ29-
cytb5109ÿ134, and PLN1ÿ44-cytb5124ÿ134 were coexpressed
with SERCA2a (Fig. 1). While the apparent synthesis of
PLN1ÿ21-cytb5101ÿ134 and PLN1ÿ29-cytb5109ÿ134 was very
low, the synthesis of PLN1ÿ44-cytb5124ÿ134 was approximately
equivalent to the level of synthesis routinely obtained with the
strongly inhibitory domain II mutant, I47A, described else-
where [15]. None of the chimeric mutants appeared to be
oligomeric in SDS-PAGE.
Evaluation of the level of expression of PLN1ÿ44-
cytb5124ÿ134 was also carried out by measurement of the
amount of 32P incorporated into PLN or PLN constructs
(Fig. 2). The fact that the chimeric PLN was phosphorylated
by protein kinase A suggests that domain Ia was properly
folded in the chimera and that it was inserted in the mem-
brane in the proper orientation, with the phosphorylation site
on the cytoplasmic surface.
Targeting of the chimeric protein to the appropriate intra-
cellular membrane was tested using confocal microscopy of
permeabilized and antibody-treated cells to determine whether
antibodies raised against SERCA2a and against PLN would
be localized to the endoplasmic reticulum and whether the
two antibodies would be colocalized. The results shown in
Fig. 3 demonstrate that both SERCA2a and the PLN1ÿ44-
cytb5124ÿ134 chimera were colocalized in the endoplasmic re-
ticulum.
Data in Table 1 demonstrate that coexpression of SER-
CA2a with PLN shifts the apparent KCa (the Ca2 concen-
tration required for half-maximal Ca2 transport, expressed in
pCa units) for SERCA2a from 6.59 to 6.25. Coexpression of
SERCA2a with mutant I47A reduced apparent KCa from 6.59
to 6.12. Coexpression of SERCA2a with approximately
the same concentration of chimeric mutant PLN1ÿ44-
cytb5124ÿ134 did not result in any signi¢cant change in appar-
ent KCa.
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Fig. 1. Immunoblottong of SERCA2a and PLN constructs. Micro-
somal fractions were isolated from HEK-293 cells and 10 Wg of pro-
tein were separated on 12.5% polyacrylamide gels. The gels were
divided horizontally at a level corresponding to the mobility of
46 kDa. The upper segment was transferred electrophoretically to a
0.45 Wm nitrocellulose membrane over a 90 min period and the ni-
trocellulose strip was incubated with anti-SERCA2 monoclonal anti-
body IID8F6. The lower segment was transferred to 0.05 Wm nitro-
cellulose membranes for 45 min period and the nitrocellulose strip
was incubated with anti-phospholamban antibody 1D11. HRP-con-
jugated anti-mouse IgG (Promega) was used as the secondary anti-
body. After addition of the substrates for chemiluminescence, the
membranes were exposed to Kodak Biomax M ¢lm for 5 s (SER-
CA2), 1 min (PLN1ÿ21-cytb5101ÿ134 and PLN1ÿ29-cytb5109ÿ134) and
15 s for PLN and other PLN constructs. PLNp and PLNm refer to
pentameric and monomeric forms of PLN, respectively.
Fig. 2. Phosphorylation of PLN, PLN1ÿ44-cytb5124ÿ134 and
PLN(I47A). Microsomes (20 Wg) were phosphorylated with 25 U of
the catalytic subunit of cAMP-dependent protein kinase (Sigma) in
30 Wl of 0.15 M KCl, 0.25 M sucrose, 10 mM Tris-HCl, pH 7.5,
20 WM CaCl2, 10 mM MgCl2, 3 mM L-mercaptoethanol, 25 mM
NaF and 25 WM [Q-32P]ATP for 5 min at room temperature. The
phosphorylated microsomes were washed by centrifugation and sep-
arated on a 12.5% polyacrylamide gel without boiling. The gel was
dried and exposed to Kodak Biomax MR ¢lm for 6 h at 370‡C
with an intensifying screen.
Table 1
E¡ects of PLN/cytb5 chimeras on the apparent a⁄nity of SERCA2a for Ca2
Constructs coexpressed with SERCA2a KCa (pCa) n
None 6.59 þ 0.08 15
PLN 6.25 þ 0.09* 15
PLN1ÿ21-cytb5101ÿ134 6.62 þ 0.042 5
PLN1ÿ29-cytb5109ÿ134 6.61 þ 0.052 5
PLN1ÿ44-cytb5124ÿ134 6.55 þ 0.122 4
PLN(I47A) 6.12 þ 0.11*2 8
KCa is the Ca2 concentration at which half-maximal Ca2 uptake rates were observed, expressed in pCa units. Data are mean values expressed in
pCa units þ S.D. *P6 0.05 vs. none by analysis of variance, followed by the Sche¡eŁ F-test. 2P6 0.05 vs. PLN by analysis of variance, followed by
the Sche¡eŁ F-test.
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4. Discussion
It is not entirely clear whether cytoplasmic PLN/SERCA2a
interactions contribute to the inhibition of SERCA2a func-
tion, since publications on this subject are contradictory
[9,10,12,21]. In our earlier experiments, interactions between
transmembrane helices of PLN and SERCA2a were clearly
inhibitory and could account for the major properties of
PLN inhibition [14]. Because the cytoplasmic phosphorylation
site was missing or inaccessible to protein kinase A in our
truncated constructs, reversal of inhibition by phosphoryla-
tion of the cytoplasmic domain was not demonstrable. Inhib-
ition could be reversed in our experiments, however, by addi-
tion of a Flag antibody to an inhibitory Flag-tagged domain
II sequence.
Our attempts to demonstrate inhibitory interactions be-
tween PLN domain I and SERCA2a through coexpression
of SERCA2a with a chimera composed of PLN domain Ia,
domain Ib, part of domain II and part of the transmembrane
domain of cytochrome b5 were negative. These negative
results, however, are in line with our earlier observations
that the cytoplasmic domain of PLN is not required for
inhibitory interactions [14] and that even minor alterations
in PLN domain II lead to loss of inhibitory function [15].
There are, however, several caveats in this approach. One
concern is the level of synthesis that we could obtain. The
level of synthesis (Figs. 1 and 2) appears to be low, but is,
in fact, underestimated by the transfer and blotting tech-
niques used. The very small size and hydrophobicity of the
monomeric PLN and PLN/cytb5 chimeras ensures that they
will not be completely captured on nitrocellulose blots.
Accordingly, we have used a monomeric mutant, I47A, as
a standard for measurement of synthesis. Under condi-
tions where comparable levels of monomeric protein were
found adhering to nitrocellulose blots (Fig. 1), I47A was
highly inhibitory, but the PLN/cytb5 chimera was not inhib-
itory.
The potential caveats of misfolding and improper orienta-
tion of the chimera in the membrane have been addressed by
demonstration of phosphorylation of the chimera (Fig. 2).
The caveat of potential mistargeting has been addressed by
studies of the colocalization of the chimeric PLN and SER-
CA2a presented in Fig. 3.
A ¢nal potential caveat is the possibility that expression of
a di¡erent transmembrane sequence simply prevents the close
association of PLN with SERCA2a that might be required for
inhibitory cytoplasmic interactions. We cannot rule out this
possibility, but we point out that 14 of the 22 residues in the
transmembrane sequence were derived from PLN in the
PLN1ÿ44-cytb5124ÿ134 chimera. While many point mutations
in the remaining eight transmembrane amino acids will dis-
rupt PLN/SERCA2a interactions, there is no reason to believe
that their alteration would mislocate PLN in its steric rela-
tionship to the cytoplasmic interaction site in SERCA2a.
Moreover, the fact that PLN domain I has the potential for
attachment to and detachment from its binding site on SER-
CA2a [5] suggests that domain I might have more £exibility
than the lipid-bound domain II in approaching its interaction
site on SERCA2a and might not be hindered in this interac-
tion by its membrane tether.
The approach of presenting domain I to SERCA2a in dif-
ferent contexts has produced variable results when Vmax is
measured [9,10,12], but has consistently shown no e¡ect on
KCa. PLN does not a¡ect Vmax of SERC2a, or a¡ects it only
marginally, at physiological molar ratios [6,12,21,22]. The ef-
fects on Vmax of domain I alone were observed only at a high
molar ratios of domain I to SERCA2a [9,10]. The modulation
of KCa of SERCA2a by PLN domain I [4,12,13,20^24] or
domain I mutants [6] was observed when domain I was con-
nected to an intact and functional domain II. On the other
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Fig. 3. Colocalization of SERCA2a and PLN1ÿ44-cytb5124ÿ134, coexpressed in HEK-293 cells. Cells were incubated with rabbit polyclonal anti-
body C4 against SERCA2a [19] and mouse monoclonal antibody 1D11 against PLN [20], followed by incubation with FITC-labelled anti-rab-
bit IgG and TRITC-labelled anti-mouse IgG and examination by confocal microscopy. a: Transfection with SERCA2a and PLN. b: Transfec-
tion with SERCA2a and PLN1ÿ44-cytb5124ÿ134. c : Transfection with pMT2 vector only. d: Transfection with SERCA2a only. In the fourth
panels of sections a and b, the ¢rst antibody was omitted.
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hand, removal of domain I did not diminish the inhibitory
e¡ect on KCa of the truncated PLN constructs [14]. Thus
domain II does not require domain I to exert its inhibitory
function, while domain I requires connection to a functional
domain II to manifest its regulatory function. These ¢ndings
led us to propose that the interaction between PLN domain II
and SERCA2a transmembrane helices is inhibitory, but that
the inhibitory interactions can be modulated by the non-in-
hibitory interactions which occur between cytoplasmic do-
mains in the two proteins [14,15]. Functional communication
between these widely separated domains must occur through
long-range coupling, mimicking the long-range transmission
of forces between sites of ATP binding in the cytoplasmic
domain of SERCA molecules and the Ca2 binding and trans-
location sites in the transmembrane domain of the same mol-
ecules, which results in Ca2 translocation [25]. In the PLN/
SERCA2a heterodimer, however, transmission of forces may
follow circuits involving both molecules. This study extends
our earlier studies by showing that the presentation of domain
Ia, domain Ib and part of domain II attached to part of the
transmembrane sequence of cytochrome b5, under conditions
where the chimeric protein is coexpressed with SERCA2a and
colocalized, in the proper topological orientation, also fails to
a¡ect any alteration in KCa of SERCA2a.
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